Figure 1 (Ocrevus 01)
The text suggests a comparison between two medications, REBIF 44 mg and EVUS 600 mg, in terms of reducing the risk of confirmed disability progression. A risk reduction of 40% is indicated with HR (95% CI) 0.60 (0.45, 0.81); p=0.0006. The proportion of patients having confirmed disability progression is shown to be 15.2% with REBIF and 9.8% with EVUS. The data also includes the number of patients at risk over time for each medication. The information is based on a study with sample sizes of 629 for REBIF and 627 for EVUS.*